Power to Decide Applauds FDA Announcement on Medication Abortion 

Press release

Power to Decide Applauds FDA Announcement on Medication Abortion 

January 3, 2023

(Washington, DC) Power to Decide issued the following statement in response to today’s announcement by the U.S. Food and Drug Administration (FDA) expanding the number of pharmacies that will be permitted to provide mifepristone, part of the two-pill medication abortion regimen.

The following statement can be attributed to Power to Decide CEO Raegan McDonald-Mosley, MD, MPH:

“We hope that pharmacies across the country will act on today’s decision by the FDA to expand access to abortion care and allow people to get the medication they need at their local pharmacy.

“Medication abortion has been a revolutionary advancement in reproductive health care, and has played a growing role in abortion care since it was first approved for use in the United States over twenty years ago. More than half of all abortions now occur with medication abortion, and thanks to today’s action by the FDA, people will more readily have access to this safe, effective medication.

“Of course, this decision alone will not solve the growing reproductive health care crisis fueled by the overturning of Roe v. Wade and the myriad state bans and restrictions on abortion care. Nonetheless, it is wonderful news and a welcome step forward.”